Eli Lilly & Co said lower than expected quarterly results due to price pressure on major products, while the drugmaker said it would continue its intention to introduce a new Covid-19 antibody treatment despite setback in one of many clinical studies on its uses
The Indianapolis-based company said it will continue to pursue US authorization of an antibody-based drug to treat patients with Covid-19 at the onset of illness and with a mild to moderate version of disease This comes after the National Allergy Institute
Eli Lilly and Company, Coronavirus, antibodies, hospital care, monoclonal antibody therapy
News from the world – EN – Eli Lilly’s income, trial stopped on the drug Covid-19 disappoint investors
